Oxford Nanopore Technologies plc (ONT.L)

96.90 +3.80 (+4.08%) At close: 04:35PM BST

Oxford Nanopore Technologies plc

Gosling Building
Edmund Halley Road Oxford Science Park
Oxford OX4 4DQ
United Kingdom
44 84 5034 7900
https://nanoporetech.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 1,238

Key executives

Name	Title	Pay	Exercised	Year born
Dr. Gurdial Singh Sanghera	Co-Founder, CEO & Non-Executive Director	1.59M	N/A	1961
Mr. Timothy Cowper	COO & Director	894.98k	N/A	1965
Dr. James Spike Willcocks	Chief Strategy Officer & Director	1.19M	N/A	N/A
Prof. Hagan Bayley Ph.D.	Co-Founder & Member of Technical Advisory Board	N/A	N/A	N/A
Mr. Nicholas Patrick Keher	CFO & Director	N/A	N/A	1982
Mr. Jordan Herman	Senior VP & General Counsel	N/A	N/A	N/A
Mr. John Schoellerman	Senior Vice President of Corporate & Business Development	N/A	N/A	N/A
Mr. Richard Compton	Senior Vice President of Sales & Commercial Operations	N/A	N/A	N/A
Ms. Sara Agee Le	Vice President of Global Marketing	N/A	N/A	N/A
Ms. Sarah Lapworth	Senior Vice President of Global Human Resources	N/A	N/A	N/A

Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in GBp.

Description

Oxford Nanopore Technologies plc engages in the research, development, manufacture, and commercialization of a nanopore based sequencing platform that allows the real-time analysis of deoxyribonucleic acid (DNA) or ribonucleic acid (RNA) in the Americas, Europe, the Middle East, Africa, India, and the Asia Pacific. The company operates in Life Science Research Tools and Covid Testing segments. It offers MinION, a portable device for DNA and RNA; GridION, a flexible and self-contained benchtop nanopore sequencer to run and analyse up to five MinION or Flongle flow cells; MinION Mk 1C, a nano pore-based sequencer with analysis software and connectivity for self-contained and portable sequencing; Flongle, an adapter for MinION or GridION that enables DNA sequencing or cDNA sequencing on smaller and single-use flow cells; and PromethION 2 Solo, a sequencer for two PromethION flow cells. The company also provides PromethION 2, a self-contained benchtop nanopore sequencer; PromethION 24, which provides single or multiple users with access to terabases of sequencing data; PromethION 48, a sequencing device with high-output flow cells; VolTRAX, an automated library prep for nanopore analyses; and Q-Line, a sequencing for applied applications, as well as products for SAR-Cov-2 testing. Its platform enables its customers to perform scientific/biomedical research in a range of areas, including human genetics, cancer research, outbreak surveillance, environmental analysis, pathogens/antimicrobial resistance, microbiome analysis, and crop science. The company was formerly known as Oxford NanoLabs Limited and changed its name to Oxford Nanopore Technologies plc in May 2008. Oxford Nanopore Technologies plc was incorporated in 2005 and is headquartered in Oxford, the United Kingdom.

Corporate governance

Oxford Nanopore Technologies plc’s ISS governance QualityScore as of 1 April 2024 is 8. The pillar scores are Audit: 3; Board: 8; Shareholder rights: 9; Compensation: 8.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.